FrancophonIA/ELRC3.0 huggingface dataset:
English: reduced sense of touch - racing heart, a sensation of a rapid, forceful, or irregular beating of the heart - vomiting, dry mouth, diarrhoea - excessive sweating - muscle spasms - feeling of exhaustion, weakness, discomfort or uneasiness, feeling strange - weight loss
Slovenian: Pogosti (lahko se pojavijo pri največ 1 od 10 bolnikov) - izguba apetita - težave s spanjem, zmedenost, občutek nemira, zmanjšana spolna sla - zaspanost, trzanje telesa, manjša zbranost, nenavaden občutek na koži, kot sta zbadanje in mravljinčenje, zmanjšana občutljivost na dotik - hitro bitje srca, občutek hitrega, silovitega, ali nepravilnega bitja srca - bruhanje, suha usta, driska - prekomerno potenje - mišični krči - občutek izčrpanosti, slabost, nelagodje, nenavadno počutje - zmanjšanje telesne mase
English: - Each film-coated tablet contains 18.06 milligram nalmefene (as hydrochloride dihydrate) - The other ingredients are:
Slovenian: - Ena filmsko obložena tableta vsebuje 18,06 miligrama nalmefena (v obliki nalmefenijevega klorida dihidrata).
English: The TAC was 102 g/day at baseline in the Selincro group (n=171) and 99 g/day at baseline in the placebo group (n=167).
Slovenian: V izhodišču je bila TAC 102 g/dan v Selincro skupini (n=171) in 99 g/dan v placebo skupini (n=167).
English: The TAC was 100 g/day at baseline in the Selincro group (n=141) and 101 g/day at baseline in the placebo group (n=42).
Slovenian: V izhodišču je bila TAC 100 g/dan v Selincro skupini (n=141) in 101 g/dan v placebo skupini (n=42).
English: double-blind, parallel-group, placebo-controlled 1-year study.
Slovenian: Učinkovitost zdravila Selincro je bila prav tako ocenjena v randomizirani, dvojno slepi, z vzporednima skupinama in s placebom nadzorovani enoletni študiji.
English: The TAC was 113 g/day at baseline in the Selincro group (n=148) and 108 g/day at baseline in the placebo group (n=155).
Slovenian: V izhodišču je bila TAC 113 g/dan v Selincro skupini (n=148) in 108 g/dan v placebo skupini (n=155).
English: The following side effects have been reported with Selincro:
Slovenian: Pri uporabi zdravila Selincro so poročali o naslednjih neželenih učinkih:
English: There seems to be a small impairment in cognitive and psychomotor performance after administration of nalmefene.
Slovenian: Po jemanju nalmefena pride do manjšega poslabšanja kognitivnih in psihomotoričnih sposobnosti.
English: Selincro is not recommended during pregnancy.
Slovenian: Zdravila Selincro ne uporabljajte pri nosečnicah.
English: Side effects such as disturbance in attention, feeling abnormal, nausea, dizziness, somnolence, insomnia, and headache may occur when beginning Selincro treatment.
Slovenian: Na začetku zdravljenja z zdravilom Selincro se lahko pojavijo neželeni učinki, kot so motnje pozornosti, nenormalno počutje, siljenje na bruhanje, omotica, somnolenca (otopelost), nespečnost in glavobol.
English: What Selincro contains
Slovenian: Kaj vsebuje zdravilo Selincro
English: For the patients who continued in the study and provided efficacy data at 1 year, the TAC was 24 g/day in the Selincro group (n=78) and 47 g/day in the placebo group (n=29).
Slovenian: Za bolnike, ki so nadaljevali v študiji in zagotovili podatke o učinkovitosti pri 1. letu, je bila TAC 24 g/dan v Selincro skupini (n=78) in 47 g/dan v placebo skupini (n=29).
English: For HDDs there were 23 days/month at baseline in the Selincro group (n=171) and 23 days/month at baseline in the placebo group (n=167).
Slovenian: V izhodišču je bilo HDDs 23 dni/mesec v Selincro skupini (n=171) in 23 dni/mesec v placebo skupini (n=167).
English: Selincro is for oral use.
Slovenian: Zdravilo Selincro je namenjeno peroralni uporabi.
English: For HDDs there were 23 days/month at baseline in the Selincro group (n=148) and 22 days/month at baseline in the placebo group (n=155).
Slovenian: V izhodišču je bilo HDDs 23 dni/mesec v Selincro skupini (n=148) in 22 dni/mesec v placebo skupini (n=155).
English: No dose adjustment is recommended for patients with mild or moderate renal impairment (see sections 4.4 and 5.2).
Slovenian: Za bolnike z blago do zmerno okvaro jeter ni priporočenega prilagajanja odmerka (glejte poglavji 4.4 in 5.2).
English: For HDDs there were 19 days/month at baseline in the Selincro-group (n=141) and19 days/month at baseline in the placebo group (n=42).
Slovenian: V izhodišču je bilo HDDs 19 dni/mesec v Selincro skupini (n=141) in 19 dni/mesec v placebo skupini (n=42).
English: For patients with mild, moderate or severe renal impairment the AUC for nalmefene was 1.1 times, 1.4 times and 2.4 times higher, respectively.
Slovenian: AUC za nalmefen je bila 1,1-krat večja za bolnike z blago okvaro ledvic, 1,4-krat večja za bolnike z zmerno okvaro ledvic in 2,4-krat večja za bolnike s hudo okvaro ledvic.
English: For the patients who continued in the study and provided efficacy data at 1 year, the number of HDDs was 5 days/month in the Selincro group (n=78) and 10 days/month in the placebo group (n= 29).
Slovenian: Za bolnike, ki so nadaljevali v študiji in zagotovili podatke o učinkovitosti pri 1. letu, je bilo število HDDs 5 dni/mesec v Selincro skupini (n=78) in 10 dni/mesec v placebo skupini (n=29).
English: For the patients who continued in the study and provided efficacy data at Month 6, the TAC was 40 g/day in the Selincro-group (n=85) and 57 g/day in the placebo group (n=114).
Slovenian: Za bolnike, ki so nadaljevali v študiji in zagotovili podatke o učinkovitosti pri 6. mesecu, je bila TAC 40 g/dan v Selincro skupini (n=85) in 57 g/dan v placebo skupini (n=114).
English: For the patients who continued in the study and provided efficacy data at Month 6, the number of HDDs was 10 days/month in the Selincro group (n=103) and 12 days/month in the placebo group (n=111).
Slovenian: Za bolnike, ki so nadaljevali v študiji in zagotovili podatke o učinkovitosti pri 6. mesecu, je bilo število HDDs 10 dni/mesec v Selincro skupini (n=103) in 12 dni/mesec v placebo skupini (n=111).
English: For the patients who continued in the study and provided efficacy data at Month 6, the TAC was 44 g/day in the Selincro group (n=103) and 52 g/day in the placebo group (n=111).
Slovenian: Za bolnike, ki so nadaljevali v študiji in zagotovili podatke o učinkovitosti pri 6. mesecu, je bila TAC 44 g/dan v Selincro skupini (n=103) in 52 g/dan v placebo skupini (n=111).
English: Restlessness
Slovenian: Nespečnost
English: For the patients who continued in the study and provided efficacy data at Month 6, the number of HDDs was 9 days/month in the Selincro group (n=85) and 14 days/month in the placebo group (n=114).
Slovenian: Za bolnike, ki so nadaljevali v študiji in zagotovili podatke o učinkovitosti pri 6. mesecu, je bilo število HDDs 9 dni/mesec v Selincro skupini (n=85) in 14 dni/mesec v placebo skupini (n=114).
English: Fatigue Asthenia
Slovenian: Utrujenost Astenija
English: Nalmefene was shown to have skin sensitisation potential in the Local Lymph Node Assay in mice after topical application.
Slovenian: Lokalna analiza limfnih vozlov pri miših je pokazala, da ima nalmefen potencial za povzročanje preobčutljivosti kože po topikalni uporabi.
English: How to store Selincro
Slovenian: Shranjevanje zdravila Selincro
English: Opioid administration
Slovenian: Uporaba opioidov
English: Comorbidity
Slovenian: Komorbidnost
English: Tablet coating
Slovenian: filmsko obložena tableta (tableta)
English: Sleep disorder
Slovenian: Ledvična okvara
English: Dissociation
Slovenian: Odmerjanje
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Slovenian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom zdravljenje raka.
English: This means that Topotecan Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU).
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU).
English: This is repeated every 21 days for six courses or until the disease gets worse.
Slovenian: To ponavljamo na vsakih 21 dni, vsega skupaj šestkrat ali dokler se stanje bolezni ne poslabša.
English: For full details, see the Summary of Product Characteristics (also part of the EPAR).
Slovenian: Za vse podrobnosti glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
English: The full EPAR for Topotecan Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Topotecan Hospira je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This document is a summary of the European Public Assessment Report (EPAR) for Topotecan Hospira.
Slovenian: Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Topotecan Hospira.
English: Topotecan Hospira topotecan
Slovenian: Topotecan Hospira topotekan
English: For more information about treatment with Topotecan Hospira, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Topotecan Hospira preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The patient's blood levels of white blood cells, platelets and haemoglobin should be checked before treatment, to ensure that they are above set minimum levels.
Slovenian: Pred zdravljenjem je treba preveriti bolnikove ravni belih krvnih celic, trombocitov in hemoglobina za zagotovitev, da te presegajo najnižje določene ravni.
English: It is also used together with cisplatin (another anticancer medicine) to treat women with cervical cancer (cancer of the cervix), when the cancer has come back after radiotherapy, or when the disease is at an advanced stage (stage IVB: the cancer has spread beyond the cervix).
Slovenian: Zdravilo se uporablja tudi skupaj z zdravilom cisplatin (drugo vrsto zdravila proti raku) za zdravljenje žensk z rakom materničnega vratu, če se je rak znova pojavil po že končanem zdravljenju z obsevanjem ali če je bolezen v napredovalem stadiju (stadij IVB: rak se je razširil zunaj materničnega vratu).
English: The European Commission granted a marketing authorisation valid throughout the EU for Topotecan Hospira on 10 June 2010.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Topotecan Hospira, veljavno po vsej Evropski uniji, izdala 10. junija 2010.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Topotecan Hospira.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Treatment with Topotecan Hospira should only be given under the supervision of a doctor experienced in the use of chemotherapy.
Slovenian: Zdravljenje z zdravilom Topotecan Hospira lahko poteka samo pod nadzorom zdravnika, ki ima izkušnje z uporabo kemoterapije.
English: The CHMP concluded that, in accordance with EU requirements, Topotecan Hospira has been shown to be comparable to Hycamtin.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Topotecan Hospira primerljivo zdravilu Hycamtin.
English: When used with cisplatin in cervical cancer, Topotecan Hospira is given on days 1, 2 and 3 (with cisplatin given on day 1).
Slovenian: Kadar se pri zdravljenju raka materničnega vratu zdravilo Topotecan Hospira uporablja skupaj s cisplatinom, se daje na 1., 2. in 3. dan (cisplatin se daje na 1. dan).
English: Because Topotecan Hospira produces the same levels of the active substance in the body as the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Slovenian: Ker zdravilo Topotecan Hospira vsebuje isto zdravilno učinkovino kot referenčno zdravilo, se šteje, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The reference medicine Hycamtin is available as a powder to be made up into a solution for infusion and not as a concentrate.
Slovenian: Referenčno zdravilo Hycamtin je na voljo v obliki praška za pripravo raztopine za infundiranje in ne v obliki koncentrata.
English: For lung cancer, Topotecan Hospira is given every day for five days with a three-week interval between the start of each course.
Slovenian: Pri pljučnem raku se zdravilo Topotecan Hospira daje vsak dan pet dni zapored, čemur sledi tritedenski premor pred pričetkom novega ciklusa zdravljenja.
English: The dose of Topotecan Hospira to be used depends on the type of cancer that it is being used to treat and the patient's weight and height.
Slovenian: Odmerek zdravila Topotecan Hospira je odvisen od vrste raka, ki ga zdravimo, ter bolnikove telesne mase in višine.
English: What are the benefit and risk of Topotecan Hospira?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Topotecan Hospira?
English: Topotecan Hospira is a ‘hybrid medicine'.
Slovenian: Topotecan Hospira je „hibridno zdravilo“.
English: Other information about Topotecan Hospira:
Slovenian: Druge informacije o zdravilu Topotecan Hospira:
English: The Committee recommended that Topotecan Hospira be given marketing authorisation.
Slovenian: Priporočil je, da se za zdravilo Topotecan Hospira izda dovoljenje za promet.
English: Topotecan Hospira also affects non-cancer cells, which causes side effects.
Slovenian: Zdravilo Topotecan Hospira vpliva tudi na nerakave celice, kar povzroča neželene učinke.
English: The active substance in Topotecan Hospira, topotecan, is an anticancer medicine that belongs to the group ‘topoisomerase inhibitors'.
Slovenian: Zdravilna učinkovina v zdravilu Topotecan Hospira, topotekan, je zdravilo za zdravljenje raka, ki spada v skupino zaviralcev topoizomeraze.
English: Topotecan Hospira is a concentrate that is made up into a solution for infusion (drip into a vein).
Slovenian: Zdravilo Topotecan Hospira je koncentrat za pripravo raztopine za infundiranje (kapalne infuzije v veno).
English: Topotecan Hospira is used on its own to treat small cell lung cancer, when the cancer has relapsed (come back).
Slovenian: Zdravilo Topotecan Hospira se uporablja samostojno za zdravljenje drobnoceličnega raka pljuč, kadar se rakavo obolenje ponovi.
English: Infusions should be carried out in a specialised cancer ward.
Slovenian: Infundiranje je treba izvajati na specializiranem oddelku za
English: Why has Topotecan Hospira been approved?
Slovenian: Zakaj je bilo zdravilo Topotecan Hospira odobreno?
English: The doses may need to be adjusted or other medicines given to the patients, when the level of white blood cells remains particularly low.
Slovenian: Če je raven belih krvnih celic še posebno nizka, je treba odmerke prilagoditi ali bolniku začeti dajati druga zdravila.
English: No additional studies were needed as Topotecan Hospira is given by infusion and contains the same active substance as the reference medicine, Hycamtin.
Slovenian: Zdravilo Topotecan Hospira se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Hycamtin, zato niso bile potrebne nobene dodatne študije.
English: How has Topotecan Hospira been studied?
Slovenian: Kako je bilo zdravilo Topotecan Hospira raziskano?
English: What is Topotecan Hospira?
Slovenian: Kaj je zdravilo Topotecan Hospira?
English: How is Topotecan Hospira used?
Slovenian: Kako se zdravilo Topotecan Hospira uporablja?
English: What is Topotecan Hospira used for?
Slovenian: Za kaj se zdravilo Topotecan Hospira uporablja?
English: How does Topotecan Hospira work?
Slovenian: Kako zdravilo Topotecan Hospira deluje?
English: It is used on its own when other treatments have not worked or are not suitable.
Slovenian: Samostojno se uporablja, kadar druga zdravljenja niso delovala ali niso primerna.
English: Further information on Kanjinti can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Več informacij o zdravilu Kanjinti je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This means that Kanjinti is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Slovenian: To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
English: What measures are being taken to ensure the safe and effective use of Kanjinti?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Kanjinti?
English: The infusion may cause allergic reactions, so the patient should be monitored during and after the infusion.
Slovenian: Infuzija lahko povzroči alergijske reakcije, zato je treba bolnika spremljati med infundiranjem in po njem.
English: Kanjinti can cause cardiotoxicity (harm to the heart), including heart failure (when the heart does not work as well as it should).
Slovenian: Zdravilo Kanjinti lahko povzroča kardiotoksičnost (škoduje srcu), vključno s srčnim popuščanjem (srce ne deluje tako dobro, kot bi moralo).
English: • metastatic breast cancer (cancer that has spread to other parts of the body).
Slovenian: • metastatskega raka dojk (raka, ki se je razširil na druge dele telesa).
English: An overview of Kanjinti and why it is authorised in the EU
Slovenian: Pregled zdravila Kanjinti in zakaj je odobreno v EU
English: The most common or serious side effects with Kanjinti are heart problems, reactions related to the Kanjinti infusion, reduced levels of blood cells (especially white blood cells), infections and lung problems.
Slovenian: Najpogostejši ali resni neželeni učinki zdravila Kanjinti so težave s srcem, reakcije, povezane z infundiranjem zdravila Kanjinti, zmanjšana količina krvnih celic (zlasti belih krvnih celic), okužbe in težave s pljuči.
English: As for all medicines, data on the use of Kanjinti are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Kanjinti stalno spremljajo.
English: Care should be taken if it is given to patients who already have heart problems or high blood pressure, and all patients need to be monitored during and after treatment to check their heart.
Slovenian: Posebna pozornost je potrebna, če se zdravilo daje bolnikom, ki že imajo težave s srcem ali visok krvni tlak, vse bolnike pa je treba med zdravljenjem in po njem spremljati glede delovanja srca.
English: What benefits of Kanjinti have been shown in studies?
Slovenian: Kakšne koristi zdravila Kanjinti so se pokazale v študijah?
English: Kanjinti is a cancer medicine used to treat the following conditions:
Slovenian: Kanjinti je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje naslednjih bolezni:
English: In addition, one study involving 696 patients with early breast cancer that overexpressed HER2 showed that Kanjinti was effective in treating the condition.
Slovenian: Poleg tega je ena študija, v katero je bilo vključenih 696 bolnikov z zgodnjim rakom dojke, ki je čezmerno izražal beljakovino HER2, pokazala, da je zdravilo Kanjinti učinkovito pri zdravljenju te bolezni.
English: Why is Kanjinti authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Kanjinti odobreno v EU?
English: Side effects reported with Kanjinti are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Kanjinti, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: What is Kanjinti and what is it used for?
Slovenian: Kaj je zdravilo Kanjinti in za kaj se uporablja?
English: The dose depends on the patient's body weight, on the condition being treated and on whether Kanjinti is given every week or every 3 weeks.
Slovenian: Odmerek je odvisen od telesne mase bolnika, od zdravljene bolezni in od tega, ali se zdravilo Kanjinti daje vsak teden ali vsake tri tedne.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kanjinti have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Kanjinti upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: For more information about using Kanjinti, see the package leaflet or contact a doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Kanjinti glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: Kanjinti must not be used in people who are hypersensitive (allergic) to trastuzumab, mouse proteins or to any of the other ingredients.
Slovenian: Zdravila Kanjinti ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) trastuzumab, mišje beljakovine ali na katero koli drugo sestavino zdravila.
English: By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the tumour cells.
Slovenian: Trastuzumab ob vezavi na beljakovino HER2 aktivira celice imunskega sistema, ki nato uničijo tumorske celice.
English: Kanjinti can only be obtained with a prescription and treatment should be started by a doctor who has experience in the use of cancer medicines.
Slovenian: Predpisovanje in izdaja zdravila Kanjinti je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
English: After treatment of up to a year, 48% of those given Kanjinti (172 of 358) and 41% of those given the reference medicine Herceptin (137 of 338) had no invasive cancer cells in the breasts or surrounding lymph nodes.
Slovenian: Po zdravljenju, ki je trajalo do enega leta, se invazivne rakave celice niso pojavile v dojkah ali okoliških bezgavkah pri 48 % (172 od 358) bolnikov, ki so prejemali zdravilo Kanjinti, in pri 41 % (137 od 338) bolnikov, ki so prejemali referenčno zdravilo Herceptin.
English: For cancers that are locally advanced (including those that are inflammatory) or more than 2 cm wide, Kanjinti is used before surgery in combination with chemotherapy and then again after surgery on its own;
Slovenian: Pri lokalno napredovalih rakih (vključno z vnetnimi tumorji) ali rakih, širših od 2 cm, se zdravilo Kanjinti uporablja pred kirurškim posegom v kombinaciji s kemoterapijo in nato samostojno po posegu;
English: What are the risks associated with Kanjinti?
Slovenian: Kakšna tveganja so povezana z zdravilom Kanjinti?
English: In the light of all the data provided the difference was not assessed to be relevant and it was concluded that Kanjinti would behave in the same way as Herceptin in its approved indications.
Slovenian: Na podlagi vseh predloženih podatkov razlike niso ocenili kot pomembne in so zaključili, da se bo zdravilo Kanjinti pri odobrenih indikacijah vedlo enako kot zdravilo Herceptin.
English: HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
Slovenian: Beljakovina HER2 je čezmerno izražena pri približno četrtini rakov dojk in petini rakov želodca.
English: It is given by infusion (drip) into a vein over 90 minutes every week or every 3 weeks for breast cancer, and every 3 weeks for gastric cancer.
Slovenian: Zdravilo se daje z 90-minutnim infundiranjem (kapalno infuzijo) v veno vsak teden ali vsake tri tedne pri raku dojk in vsake tri tedne pri raku želodca.
English: Other information about Kanjinti
Slovenian: Druge informacije o zdravilu Kanjinti
English: • early breast cancer (when the cancer has spread within the breast or to the glands under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable.
Slovenian: • zgodnjega raka dojk (kadar se je rak razširil znotraj dojke ali v podpazdušne žleze, ne pa na druge dele telesa) po kirurškem posegu, kemoterapiji (z zdravili za zdravljenje raka) in radioterapiji (zdravljenju z obsevanjem), če je smiselno.